Virpax Pharmaceuticals (VRPX) surged in recent Friday trading after the specialty medications company said injections of its Probudur drug candidate into tissue surrounding an incisional wound provided both immediate and extended pain relief in minipigs during preclinical testing to determine optimal dosing ranges.
All of the minipigs in the study showed positive tolerance to Probudur and had no adverse effects. Based on the positive results, Virpax said it would continue to work on developing human trials for Probudur as part of an eventual investigational new drug application.
The company's shares were up 47% in recent trading Friday.
Price: 0.83, Change: +0.26, Percent Change: +47.50
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。